Benzinga | May 13, 2021 08:30AM EDT

Hoth Therapeutics Provides Shareholder Update On Endocannabinoid Therapeutic For Cutaneous Lupus Erythematosus

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods(tm), a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET for interested shareholders. Adam Friedman, MD, FAAD and Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences, who has worked on the development of this novel therapeutic, will provide an overview on the burden of cutaneous lupus, the gap in care for diagnosed patients, and how HT-005 Z-Pods(tm) is designed to address both treatment and quality of life concerns for CLE patients. Dr. Friedman will also provide a brief overview of the proof-of-concept efficacy data from an animal study.